Destiny Pharma Shares Decline Despite Positive XF-73 MRSA Data

1 min read | August 05, 2024 04:53 AM PDT | By Team Kalkine Media

Google News:

Destiny Pharma Shares Decline Despite Positive XF-73 MRSA Data — Image source: Shutterstock

Recent News

Palo Alto Networks Shares Cool After Strong Market Run

Meta Platforms Faces New Questions After AI Spending Jitters

Lucid Stock Slide Raises Fresh EV Market Questions

Astera Labs Drop Sparks Fresh AI Chip Stock Debate

Make Kalkine Media
My Trusted Source

XF-73 Data Announced

Destiny Pharma PLC (LSE:DEST) announced promising results for its lead drug, exeporfinium chloride, branded as XF-73, on Monday. The Brighton-based clinical-stage biotechnology company revealed data from a recent study indicating that XF-73 reduced MRSA infection in burn wound tissue by up to 99.99% compared to a placebo treatment. This study demonstrated the drug's effectiveness following a single topical application of 25, 50, or 100 micrograms of XF-73.

Significance of MRSA Reduction

MRSA, or methicillin-resistant Staphylococcus aureus, is a dangerous pathogen known for causing severe infections and potentially life-threatening sepsis with a high mortality rate. The results from the study are seen as a significant advancement in the development of XF-73, highlighting its potential to substantially reduce or eliminate MRSA from wound sites, thereby minimizing the risk of sepsis.

Chief Scientific Officer Bill Love commented on the study's results, stating that the data from the in vivo burn wound infection model provides compelling evidence of XF-73’s capability to significantly mitigate the risk of MRSA reaching the bloodstream and causing severe infections. This outcome is considered a key milestone for the continued development of XF-73 as a dermal product.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.